Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Laboratory evaluation of ELISA and indirect immunofluorescence assay in response to emergence of Japanese encephalitis virus genotype IV in Australia.
Kinsella P, Moso M, Martin G, Karapangiotidis T, Karamalakis D, Nicholson S, Batty M, Jackson K, Marsland M, Thomson T, Manoharan L, O'brien H, Friedman ND, Bond K, Williamson DA, Lim CK. Kinsella P, et al. Among authors: thomson t. J Clin Virol. 2023 Nov;168:105580. doi: 10.1016/j.jcv.2023.105580. Epub 2023 Sep 9. J Clin Virol. 2023. PMID: 37717487 Free article.
Seroprevalence of Japanese encephalitis virus-specific antibodies in Australia following novel epidemic spread: protocol for a national cross-sectional study.
Winkler NE, Koirala A, Kaur G, Prasad S, Hirani R, Baker J, Hoad V, Gosbell IB, Irving DO, Hueston L, O'Sullivan MV, Kok J, Dwyer DE, Macartney K; Australian Japanese Encephalitis Virus Serosurvey Group; Australian Japanese encephalitis virus serosurvey group. Winkler NE, et al. BMJ Open. 2024 Feb 7;14(2):e075569. doi: 10.1136/bmjopen-2023-075569. BMJ Open. 2024. PMID: 38326269 Free PMC article.
Serosurvey for Japanese encephalitis virus antibodies following an outbreak in an immunologically naïve population, Victoria, 2022: a cross-sectional study.
Marsland MJ, Thomson TN, O'Brien HM, Peach E, Bellette J, Humphreys N, McKeon CA, Cross W, Moso MA, Batty M, Nicholson S, Karapanagiotidis T, Lim CK, Williamson DA, Winkler N, Koirala A, Macartney K, Glynn-Robinson A, Stewart T, Minko C, Snow KJ, Black J, Friedman ND. Marsland MJ, et al. Among authors: thomson tn. Med J Aust. 2024 May 27. doi: 10.5694/mja2.52344. Online ahead of print. Med J Aust. 2024. PMID: 38803004
Effects of catchment land use on temperate mangrove forests.
Thomson T, Ellis JI, Fusi M, Prinz N, Lundquist CJ, Bury SJ, Shankar U, Cary SC, Pilditch CA. Thomson T, et al. Sci Total Environ. 2024 May 30:173579. doi: 10.1016/j.scitotenv.2024.173579. Online ahead of print. Sci Total Environ. 2024. PMID: 38823713 Free article.
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, de Silva TI, Snowden JA, Lim SH, Bowden SJ, Billingham L, Richter A, Carroll M, Carr EJ, Beale R, Rea D, Parry H, Pirrie S, Lim Z, Satsangi J, Dunachie SJ, Cook G, Miller P, Basu N, Gilmour A, Hodgkins AM, Evans L, Hughes A, Longet S, Meacham G, Yong KL, A'Hearne MJ, Koh MBC, Burns SO, Orchard K, Paterson C, McIlroy G, Murray SM, Thomson T, Dimitriadis S, Goulston L, Miller S, Keillor V, Prendecki M, Thomas D, Kirkham A, McInnes IB, Kearns P; OCTAVE-DUO investigators. Goodyear CS, et al. Among authors: thomson t. Lancet Rheumatol. 2024 Jun;6(6):e339-e351. doi: 10.1016/S2665-9913(24)00065-1. Epub 2024 May 8. Lancet Rheumatol. 2024. PMID: 38734019 Free article. Clinical Trial.
307 results